

**CLEAN VERSION OF PENDING CLAIMS**

A<sup>2</sup>  
34. [Amended] A polypeptide comprising a lysosomal enzyme, a naturally secreted protein, a nuclear protein, or a cytoplasmic protein operably linked to a PTD, wherein the polypeptide is expressed from an expression vector located *in situ* in a brain cell of a patient, and wherein the polypeptide is biologically active.

35. The polypeptide of claim 34, wherein the polypeptide is a lysosomal enzyme.

36. The polypeptide of claim 34, wherein the lysosomal enzyme is a soluble lysosomal enzyme.

37. The polypeptide of claim 36, wherein the soluble lysosomal enzyme is  $\beta$ -glucuronidase, pepstatin insensitive protease or palmitoyl protein thioesterase.

A<sup>3</sup>  
38. [Amended] The polypeptide of claim 36, wherein the soluble lysosomal enzyme is  $\beta$ -glucuronidase.

39. The polypeptide of claim 34, wherein the polypeptide is a secreted protein.

40. The polypeptide of claim 39, wherein the secreted protein is a growth factor or an anti-neoplastic protein.

41. The polypeptide of claim 40, wherein the growth factor is GDNF, NGF, BDNF, or NT3.

42. The polypeptide of claim 40, wherein the anti-neoplastic protein is an inhibitor of neovascularization, cell migration, or cell proliferation.

43. The polypeptide of claim 34, wherein the polypeptide is a nuclear protein.
44. The polypeptide of claim 43, wherein the nuclear protein is a transcription factor.
45. The polypeptide of claim 34, wherein the polypeptide is a cytoplasmic protein.
46. The polypeptide of claim 45, wherein the cytoplasmic protein is a cytotoxic agent.
47. The polypeptide of claim 34, wherein the PTD is Tat PTD.
48. The polypeptide of claim 47, wherein the Tat PTD is Tat<sub>47-57</sub>.
62. [New] The polypeptide of claim 34, wherein the polypeptide is enzymatically active.